Rheumatic Heart Disease Burden: A Comparative Analysis between the United States and the European Union.

BACKGROUND

Rheumatic heart disease (RHD) is a major challenge to global health, primarily in low- and middle-income countries. Even though RHD is rare in high-income countries, it still poses a health challenge, yet there is a lack of data on its impact within the highest-income regions.

OBJECTIVES

The purpose of this study was to compare the epidemiology of RHD in the United States of America (USA) and the European Union (EU).

METHODS

Data on RHD burden were collected using the Global Disease Burden Study 2021 using the Global Health Data Exchange query tool. Age-standardized rates of incidence (ASIR), prevalence (ASPR), death (ASDR), disability-adjusted life years (ASDALY), years lived with disability (ASYLD), and years of life lost (ASYLL) were collected. Estimated annual percentage change (EAPC) was calculated.

RESULTS

In USA in 2021, the ASPR was 123.4/100,000 with a decreasing annual trend of 0.32% since 1993. Between 2021 and 1993, the ASIR decreased from 10.6 to 10.0/100,000 cases. In the EU in 2021, the ASPR was 49.7/100,000 cases, with an annual decreasing trend of 1.6% between 2021 and 1993. Between 2021 and 1993, the ASIR decreased from 7.43 to 4.6/100,000 cases. The changing prevalence and incidence in the US was primarily driven by Florida, Nevada, and Tennessee. There has been a reversal in the burden of RHD since 2007 in the USA. In both regions, there was a significant gender disparity with female predominance. The EU reported higher age-standardized disability-adjusted life years and age-standardized years of life losts than the USA.

CONCLUSIONS

The varied trends underscore the complexity of RHD epidemiology and the need for region-specific strategies to address this persistent health challenge.